Cargando…

MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease

SIMPLE SUMMARY: Multiple myeloma (MM) is the second most common haematologic malignancy, and it remains an incurable disease despite the advances of novel therapies. It is characterised by a multistep process that arises from a pre-malignant asymptomatic status-defined monoclonal gammopathy of undet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Desantis, Vanessa, Solimando, Antonio Giovanni, Saltarella, Ilaria, Sacco, Antonio, Giustini, Viviana, Bento, Marta, Lamanuzzi, Aurelia, Melaccio, Assunta, Frassanito, Maria Antonia, Paradiso, Angelo, Montagnani, Monica, Vacca, Angelo, Roccaro, Aldo M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344971/ https://www.ncbi.nlm.nih.gov/pubmed/34359551 http://dx.doi.org/10.3390/cancers13153650

Ejemplares similares

MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance
por: Desantis, Vanessa, et al.
Publicado: (2020)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2020)

Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance
por: Melaccio, Assunta, et al.
Publicado: (2022)

Role of Extracellular Vesicle-Based Cell-to-Cell Communication in Multiple Myeloma Progression
por: Saltarella, Ilaria, et al.
Publicado: (2021)

Uptake-Dependent and -Independent Effects of Fibroblasts-Derived Extracellular Vesicles on Bone Marrow Endothelial Cells from Patients with Multiple Myeloma: Therapeutic and Clinical Implications
por: Lamanuzzi, Aurelia, et al.
Publicado: (2023)

The Landscape of lncRNAs in Multiple Myeloma: Implications in the “Hallmarks of Cancer”, Clinical Perspectives and Therapeutic Opportunities
por: Saltarella, Ilaria, et al.
Publicado: (2022)

Functional and Biological Role of Endothelial Precursor Cells in Tumour Progression: A New Potential Therapeutic Target in Haematological Malignancies
por: Reale, Antonia, et al.
Publicado: (2016)

Autophagy: A New Mechanism of Prosurvival and Drug Resistance in Multiple Myeloma
por: Desantis, V., et al.
Publicado: (2018)

Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma
por: Lamanuzzi, Aurelia, et al.
Publicado: (2018)

Ion Channels in Multiple Myeloma: Pathogenic Role and Therapeutic Perspectives
por: Saltarella, Ilaria, et al.
Publicado: (2022)

Epigenetic Aberrations in Multiple Myeloma
por: Caprio, Cinzia, et al.
Publicado: (2020)

High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment
por: Solimando, Antonio Giovanni, et al.
Publicado: (2019)

The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value
por: Desantis, Vanessa, et al.
Publicado: (2022)

Cardiovascular Risk in Patients With Takayasu Arteritis Directly Correlates With Diastolic Dysfunction and Inflammatory Cell Infiltration in the Vessel Wall: A Clinical, ex vivo and in vitro Analysis
por: Cicco, Sebastiano, et al.
Publicado: (2022)

Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
por: Ria, Roberto, et al.
Publicado: (2020)

Microenvironment drug resistance in multiple myeloma: emerging new players
por: Di Marzo, Lucia, et al.
Publicado: (2016)

Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin(®) protein MP0250: a preclinical study
por: Rao, Luigia, et al.
Publicado: (2018)

Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients
por: Lamanuzzi, Aurelia, et al.
Publicado: (2016)

Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma–Enhanced Angiogenesis: A Novel Therapeutic Target?()
por: Saltarella, Ilaria, et al.
Publicado: (2018)

Anti-Angiogenic Activity of Drugs in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2023)

microRNAs as Biomarkers of Endothelial Dysfunction and Therapeutic Target in the Pathogenesis of Atrial Fibrillation
por: Desantis, Vanessa, et al.
Publicado: (2023)

Gene expression profiling of normal thyroid tissue from patients with thyroid carcinoma
por: Ria, Roberto, et al.
Publicado: (2016)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Right Heart Changes Impact on Clinical Phenotype of Amyloid Cardiac Involvement: A Single Centre Study
por: Cicco, Sebastiano, et al.
Publicado: (2020)

A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche
por: Solimando, Antonio Giovanni, et al.
Publicado: (2020)

Liquid Biopsy in Cancer: Focus on Lymphoproliferative Disorders
por: Savino, Francesco D., et al.
Publicado: (2022)

Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies
por: Ria, Roberto, et al.
Publicado: (2014)

Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma
por: Ria, Roberto, et al.
Publicado: (2012)

A multiple myeloma that progressed as type I cryoglobulinemia with skin ulcers and foot necrosis: A case report
por: Solimando, Antonio G., et al.
Publicado: (2018)

Circulating microRNAs and Their Role in Multiple Myeloma
por: Federico, Cinzia, et al.
Publicado: (2019)

Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma
por: Calcinotto, Arianna, et al.
Publicado: (2015)

Actors on the Scene: Immune Cells in the Myeloma Niche
por: Leone, Patrizia, et al.
Publicado: (2020)

STAT1 overexpression triggers aplastic anemia: a pilot study unravelling novel pathogenetic insights in bone marrow failure
por: Solimando, Antonio Giovanni, et al.
Publicado: (2023)

JAM-A as a prognostic factor and new therapeutic target in multiple myeloma
por: Solimando, A G, et al.
Publicado: (2018)

Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia
por: Sacco, Antonio, et al.
Publicado: (2010)

Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling
por: Solimando, Antonio Giovanni, et al.
Publicado: (2020)

Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression
por: Solimando, Antonio G., et al.
Publicado: (2020)

Bone Marrow Microenvironment in Multiple Myeloma Progression
por: Manier, S., et al.
Publicado: (2012)

Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma
por: Castella, Barbara, et al.
Publicado: (2018)

New Insights in Anti-Angiogenesis in Multiple Myeloma
por: Ribatti, Domenico, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vr8k04v49kb4a2nevo756amnq0